12/9/2010 8:20:20 AM
Bloomberg -- Pfizer Inc.’s breast-cancer drug Aromasin and similar treatments from AstraZeneca Plc and Novartis AG make women 20 percent more likely to develop heart disease than an older therapy, a study found. The trial, presented today at the San Antonio Breast Cancer Symposium in Texas, suggests that women already at risk for cardiac conditions should limit use of these drugs, researchers said. Tamoxifen, a generic alternative approved in 1977, carries less risk of heart complications, the study found.
comments powered by